Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-Weekly Carfilzomib + Lenalidomide + Dexamethasone in Multiple Myeloma
NCT02335983Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2015
- Primary completion
- Oct 2019
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of carfilzomib in multiple myeloma (MM) (6 arms), sponsored by Amgen. Primary endpoints: Number of Participants With Adverse Events, Change From Baseline in Hemoglobin Levels and 4 more. Started Apr 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02335983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335983.